Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Atlassian Corporation PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Atlassian Corporation PLC trades at $90.02 (market cap $22.55B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TEAM | |
|---|---|---|
Market Cap | $39.89B | $22.55B |
Sector | Health | Technology |
52-Week High | $491.22 | $203.00 |
52-Week Low | $278.09 | $57.15 |
Enterprise Value | $38.15B | $22.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Atlassian (TEAM) trades at $88.86, down 2.04% today, with strong technical momentum indicated by bullish moving averages. The company shows accelerating revenue growth reaching $5.22B in 2025, though it remains unprofitable with a -3.5% net margin. Recent earnings beats and cloud revenue growth of 29% in Q3 FY26 demonstrate business momentum, while analyst consensus remains strongly bullish with a $119.93 price target representing 35% upside potential.
TEAM presents a compelling growth story with improving fundamentals and strong analyst support, though profitability challenges and AI disruption risks require monitoring. The stock's current valuation at 3.77x sales appears reasonable given the 30%+ revenue growth trajectory, making it attractive for growth-oriented investors willing to accept near-term losses for long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
